US Patent

US8282966 — Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide

Method of Use · Assigned to INO Therapeutics LLC · Expires 2029-06-30 · 3y remaining

Vulnerability score 73/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of reducing the risk or preventing pulmonary edema in children treated with inhaled nitric oxide.

USPTO Abstract

The invention relates methods of reducing the risk or preventing the occurrence of an adverse event (AE) or a serious adverse event (SAE) associated with a medical treatment comprising inhalation of nitric oxide.

Drugs covered by this patent

Inomax (NITRIC OXIDE) · Vero Biotech Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1286`	—	Inomax
`U-1286`	—	Inomax

Patent Metadata

Patent number: US8282966
Jurisdiction: US
Classification: Method of Use
Expires: 2029-06-30
Drug substance claim: No
Drug product claim: No
Assignee: INO Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.